A trial to learn how safe AZD9550 is in people with or without type 2 diabetes who are overweight or obese - CONTEMPO

Study identifier:D8460C00002

ClinicalTrials.gov identifier:NCT06151964

EudraCT identifier:N/A

CTIS identifier:2023-504215-32-00

Recruiting

Official Title

A Phase I/II, Randomised, Single-blind, Placebo-controlled, Multiple-ascending-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD9550 in Overweight and Obese Participants with or without Type 2 Diabetes Mellitus

Medical condition

Non-alcoholic steatohepatitis (NASH)

Phase

Phase 1/2

Healthy volunteers

No

Study drug

AZD9550, Placebo

Sex

All

Estimated Enrollment

88

Study type

Interventional

Age

18 Years - 65 Years

Date

Study Start Date: 29 Sept 2023
Estimated Primary Completion Date: 04 Apr 2025
Estimated Study Completion Date: 04 Apr 2025

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Sept 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria